A new review highlights the growth of ????-???????????????? ???????????????? ?????????????????? in antibody therapeutics. Strategic design of the Fab (antigen-binding) and Fc (effector function) domains enable tailored treatments across diverse diseases. ?? Key Insights: ? Innovations in antibody engineering are unlocking new targets and formats. ? Fine-tuning Fc-mediated effector functions is essential for safety and efficacy. ? Early-stage functional assays are critical to anticipate potential risks in development. As the field continues to evolve, understanding the intricate interplay between Fab and Fc domains is crucial to designing safer, more effective antibody therapies. Read the paper here: https://lnkd.in/eitYijrX #Biointron #Antibodies #Immunotherapy #Fc #DrugDevelopment #AntibodyProduction Study by Silvia Crescioli, Shashi Jatiani & Lenny Moise
Silvia Crescioli
5 天前
Thank you so much for your post Biointron!
VP, Research at SeromYx
1 周Thank you for the post, Biointron!